EHA 2021 | Challenges of axi-cel and the future of CAR-T therapy
David Miklos, BSc, MD, PhD, Stanford University, Stanford, CA, talks on the ongoing challenges of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphomas, commenting on the impact of financial support, and the importance of communicating the benefits of axi-cel therapy to healthcare professionals and patients. Prof. Miklos also discusses the future use of axi-cel in other lymphomas and acute lymphoblastic leukemia, and discusses future directions for chimeric antigen receptor T-cell (CAR-T) therapies, with the potential development of dual-targeting CARs and allogeneic CAR-T therapies. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
David Miklos, BSc, MD, PhD, has participated in scientific or clinical advisory boards with Adaptive Biotechnologies, Novartis, Juno-Celgene-BMS, Kite-Gilead, Pharmacyclics-Abbvie, Janssen, AlloGene, Precision Bioscience, Miltenyi Biotech, Adicet and Takeda; and has performed industry contracted research for Pharmacyclics-Abbvie, Kite-Gilead, Novartis Allogene, Roche, Genentech, Becton Dickinson, Isoplexis, Miltenyi and Adaptive Biotechnologies.
